Information for investors including share information, share analysis, shareholder news and annual reports.

GSK publishes Q1 2014 pre-announcement aide memoire:

View Q1 2014 aide memoire (PDF)

GSK publishes historical quarterly restated financial information:

View restated financial information (PDF)
View restated financial information (XLSX)

stock prices
Investing in GSK

Reasons to invest in GSK - a global healthcare company enabling people to do more, feel better and live longer.

Corporate reporting

Find out how GSK is performing with our Annual Report, Corporate Responsibility Report and financial summary.

Press releases

These press releases are intended for business journalists and analysts/investors.
15 April 2014

GSK receives US approval for once-weekly type 2 diabetes treatment, Tanzeum™ (albiglutide)

GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved TanzeumTM (albiglutide) for injection, for subcutaneous use, as a once-weekly treatment for type 2 diabetes.

14 April 2014

GSK statement on BBC Panorama programme

GSK issued the following statement in response to claims by BBC Panorama related to GSK in Poland, to be broadcast on Monday April 14 2014

02 April 2014

Update on phase III clinical trial of investigational MAGE-A3 antigen-specific cancer immunotherapeutic in non-small cell lung cancer

GSK announced its decision to stop the MAGRITi trial, a Phase III trial of its MAGE-A3ii cancer immunotherapeuticiii in non-small cell lung cancer (NSCLC) patients, after establishing that it will not be possible to identify a sub-population of gene-signature positive NSCLC patients that may benefit from the treatment.

UK Map
Investor relations UK
GlaxoSmithKline plc
   Tel: 020 8047 5000
980 Great West Road
    Fax: 020 8047 7807
Middlesex TW8 9GS

Investor downloads

Our product pipeline      
Our product pipeline 0.3MB